All In Biotech

Drug Trial Radar · NCT07282665

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

A PHASE 3, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 32,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

32,500

Planned (sponsor's estimate)

Start

Dec 10, 2025

Primary completion

Dec 11, 2028

Study completion Jun 7, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot into the upper arm muscle. This study looks at the number of diarrhea (loose stools) events related to a C. difficile infection, so the length of the study can change. If these events happen quickly, the study may finish sooner; if they happen slowly, it could take longer. Sometimes, the study might stop early if the vaccine clearly does not work. Participants will stay in the study until enough events have occurred to answer the main question. On average, each person is expected to take part for up to about three and a half years. During this time, participants will have 3 planned clinic visits and 3 planned phone visits. After these visits, more scheduled clinic visits will happen every year until the end of study. Besides the scheduled study visits, if at any time during the study a participant has 3 or more loose stools in 24 hours, they will be asked to save the next one (the fourth or later) and contact the study site. The study site will check to see if it could be a C. difficile infection. This check may happen at the clinic or through a phone or video call.

Conditions

  • Clostridoides Difficile Associated Disease

Interventions

  • C.difficile vaccineBiological

    C.difficile vaccine given as an intramuscular injection

  • Saline PlaceboOther

    0.9% sodium chloride solution given as a intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of participants reporting local reactionsTime frame: For 7 days after each vaccination
  2. The percentage of participants reporting systemic eventsTime frame: For 7 days after each vaccination
  3. Percentage of participants reporting adverse eventsTime frame: From each vaccination through 1 month after each vaccination
  4. Percentage of participants reporting serious adverse eventsTime frame: From Vaccination 1 (Day 1) through 12 months after Vaccination 2 (last dose) (18 months)
  5. The incidence of the first episode of medically attended and clinically meaningful primary Clostridioides difficile infection (CDI)Time frame: from 14 days after Vaccination 2 to the end of the surveillance period (up to approximately 3.5 years)
  6. The incidence of the first episode of medically attended primary CDITime frame: from 14 days after Vaccination 2 to the end of the surveillance period (up to approximately 3.5 years)
  7. The incidence of the first episode of clinically meaningful primary CDITime frame: from 14 days after Vaccination 2 to the end of the surveillance period (up to approximately 3.5 years)

Locations

185 sites in 4 countries. Site status is shown where the registry gives one.

  • North Alabama Research Center

    Athens, Alabama · Recruiting

  • Lakeview Clinical Research

    Guntersville, Alabama · Recruiting

  • Medical Affiliated Research Center

    Huntsville, Alabama · Recruiting

  • Chinle Center for Indigenous Health

    Chinle, Arizona · Recruiting

  • Chinle Comprehensive Health Care Facility

    Chinle, Arizona · Recruiting

  • Epic Medical Research-Sun City

    Sun City, Arizona · Recruiting

  • Applied Research Center of Arkansas

    Little Rock, Arkansas · Recruiting

  • Kaiser Permanente Daly City

    Daly City, California · Recruiting

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente Oncology Pharmacy #014C

    Los Angeles, California · Recruiting

  • Sacramento VA Medical Center

    Mather, California · Recruiting

  • Kaiser Permanente Oakland

    Oakland, California · Recruiting

  • Kaiser Permanente Ontario Medical Center

    Ontario, California · Recruiting

  • Kaiser Permanente Roseville

    Roseville, California · Recruiting

  • Kaiser Permanente Sacramento

    Sacramento, California · Recruiting

  • Kaiser Permanente South Sacramento

    Sacramento, California · Recruiting

  • Velocity Clinical Research, San Bernardino

    San Bernardino, California · Recruiting

  • Kaiser Permanente - San Diego Medical Center

    San Diego, California · Recruiting

  • Kaiser Permanente Viewridge Medical Office

    San Diego, California · Recruiting

  • Kaiser Permanente San Jose

    San Jose, California · Recruiting

  • Carbon Health - San Mateo - Hillsdale Mall

    San Mateo, California · Active not recruiting

  • Kaiser Permanente Santa Clara

    Santa Clara, California · Recruiting

  • Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.

    Toluca Lake, California · Recruiting

  • Kaiser Permanente Walnut Creek

    Walnut Creek, California · Recruiting

  • Diablo Clinical Research, Inc.

    Walnut Creek, California · Recruiting

  • GW Vaccine Research Unit

    Washington D.C., District of Columbia · Recruiting

  • The GW Medical Faculty Associates

    Washington D.C., District of Columbia · Recruiting

  • Bay Pines VA Healthcare System

    Bay Pines, Florida · Recruiting

  • Proactive Clinical Research,LLC

    Fort Lauderdale, Florida · Recruiting

  • Clinical Neuroscience Solutions, LLC

    Jacksonville, Florida · Recruiting

  • M3 Wake Research - Lake City

    Lake City, Florida · Recruiting

  • South Florida Research Organization

    Medley, Florida · Recruiting

  • Care Research Inc

    Miami, Florida · Recruiting

  • Entrust Clinical Research

    Miami, Florida · Recruiting

  • Charisma Medical and Research Center

    Miami Lakes, Florida · Recruiting

  • Palm Springs Community Health Center

    Miami Lakes, Florida · Recruiting

  • Indago Research & Health Center, Inc

    Miami Lakes, Florida · Recruiting

  • Angels Clinical Research Institute

    Tampa, Florida · Recruiting

  • Emory Steiner Building Research Center

    Atlanta, Georgia · Recruiting

  • Emory University Woodruff Extension Building (WEB)

    Atlanta, Georgia · Recruiting

Showing 40 of 185 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.